How can sensitive health data be used responsibly in scientific research or how can artificial intelligence help make breakthroughs in medical research? The ECCB2024 conference brings together current themes in computational biology and international researchers in Turku, Finland.
SYS-LIFE postdoctoral programme announced the selected fellows and their projects for the first call of the programme. The next call will be opened during autumn 2024.
A new Finnish study from University of Turku shows that already a 30-minute exercise can increase the proportion of tumor-killing white blood cells in the bloodstream of breast cancer patients.
Researchers at the University of Turku in Finland have found a new function for an existing protein. They discovered that TIMP-1, a protein traditionally known to prevent damage to the body's cells and tissues, plays a critical role in the immune system's defence against cancer. The findings of the study could improve the effectiveness of current cancer immunotherapies.
Discoveries made when biology meets computational sciences are revolutionising the landscape of life sciences and healthcare. Computational biology and bioinformatics are driving this transformation, helping researchers analyse vast amounts of biological data. European Conference on Computational Biology (ECCB) is Europe’s main event in computational biology and bioinformatics this year, bringing 600–800 experts to Turku, Finland, on 16–20 September 2024.
At the joint Academic Day of the University of Turku and Åbo Akademi University on 22 March 2024, Antti Hakanen, the Docent of Clinical Microbiology at the University of Turku and the Chief of Department at Tyks Laboratories of the Wellbeing Services County of Southwest Finland, was presented with the Docent of the Year recognition.
SYS-LIFE postdoctoral research programme invites applications for 22 postdoctoral researcher positions at the University of Turku, Finland, for a fixed-term period of three years. The first call for applications opened on 5 December and closes on 31 January 2023.
Cutaneous squamous cell carcinoma (cSCC), also known as the squamous cell carcinoma of the skin, is the most common form of metastatic skin cancer. The incidence of cSCC is increasing worldwide with millions of new cases diagnosed each year. The prognosis of metastatic cSCC is poor as there are currently no effective targeted treatments available. New study conducted at the University of Turku, Finland, shows that plixorafenib, a new drug developed for treating melanoma and lung cancer, can also stop the progression of cutaneous squamous cell carcinoma.
A research group from the University of Turku and Turku Bioscience Centre together with Misvik Biology Ltd in Finland have developed a new method for studying how cancer cells function in softer and stiffer tissue environments. This insight challenges the existing paradigm, opening up new possibilities for research in cancer biology and tissue engineering.